tiprankstipranks
Trending News
More News >
Huakang Biomedical Holdings Company Limited (HK:8622)
:8622
Hong Kong Market
Advertisement

Huakang Biomedical Holdings Company Limited (8622) Price & Analysis

Compare
0 Followers

8622 Stock Chart & Stats


8622 FAQ

What was Huakang Biomedical Holdings Company Limited’s price range in the past 12 months?
Huakang Biomedical Holdings Company Limited lowest stock price was HK$0.12 and its highest was HK$0.46 in the past 12 months.
    What is Huakang Biomedical Holdings Company Limited’s market cap?
    Huakang Biomedical Holdings Company Limited’s market cap is HK$190.18M.
      When is Huakang Biomedical Holdings Company Limited’s upcoming earnings report date?
      Huakang Biomedical Holdings Company Limited’s upcoming earnings report date is Nov 18, 2025 which is in 87 days.
        How were Huakang Biomedical Holdings Company Limited’s earnings last quarter?
        Huakang Biomedical Holdings Company Limited released its earnings results on Aug 15, 2025. The company reported -HK$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.005.
          Is Huakang Biomedical Holdings Company Limited overvalued?
          According to Wall Street analysts Huakang Biomedical Holdings Company Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Huakang Biomedical Holdings Company Limited pay dividends?
            Huakang Biomedical Holdings Company Limited does not currently pay dividends.
            What is Huakang Biomedical Holdings Company Limited’s EPS estimate?
            Huakang Biomedical Holdings Company Limited’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Huakang Biomedical Holdings Company Limited have?
            Huakang Biomedical Holdings Company Limited has 500,472,000 shares outstanding.
              What happened to Huakang Biomedical Holdings Company Limited’s price movement after its last earnings report?
              Huakang Biomedical Holdings Company Limited reported an EPS of -HK$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Huakang Biomedical Holdings Company Limited?
                Currently, no hedge funds are holding shares in HK:8622

                Huakang Biomedical Holdings Company Limited Stock Smart Score

                7
                Neutral
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                Huakang Biomedical Holdings Company Limited

                Huakang Biomedical Holdings Company Limited (8622) is a healthcare company operating in the biomedical sector. The company is primarily involved in the research, development, and commercialization of biomedical products. Its core services and products include the development of innovative healthcare solutions aimed at improving health outcomes. The company is committed to advancing medical technologies and providing high-quality biomedical products to its clients.

                Huakang Biomedical Holdings Company Limited (8622) Earnings & Revenues

                8622 Stock 12 Month Forecast

                Average Price Target

                HK$0.50
                ▲(31.58% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"HK$0","1":"HK$1","-1":"-HK$1","-0.5":"-HK$0.5","0.5":"HK$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$0.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$0.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.4076923076923077,0.4153846153846154,0.4230769230769231,0.4307692307692308,0.43846153846153846,0.4461538461538462,0.45384615384615384,0.46153846153846156,0.46923076923076923,0.47692307692307695,0.4846153846153846,0.49230769230769234,{"y":0.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.4076923076923077,0.4153846153846154,0.4230769230769231,0.4307692307692308,0.43846153846153846,0.4461538461538462,0.45384615384615384,0.46153846153846156,0.46923076923076923,0.47692307692307695,0.4846153846153846,0.49230769230769234,{"y":0.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.4076923076923077,0.4153846153846154,0.4230769230769231,0.4307692307692308,0.43846153846153846,0.4461538461538462,0.45384615384615384,0.46153846153846156,0.46923076923076923,0.47692307692307695,0.4846153846153846,0.49230769230769234,{"y":0.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.14,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.18,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.2,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.17,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.14,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.15,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.38,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.32,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.31,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.36,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.4,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.4,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Fusen Pharmaceutical Co., Ltd.
                PuraPharm Corp. Ltd.
                Kontafarma China Holdings Ltd
                China NT Pharma Group Co., Ltd.
                Extrawell Pharmaceutical Holdings Limited
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis